Parkinson’s disease is characterized by a loss of dopaminergic neurons in the ventral midbrain. This disease is diagnosed when around 50% of these neurons have already died; consequently, therapeutic treatments start too late. Therefore, an urgent need exists to find new targets involved in the onset and progression of the disease. Phosphodiesterase 7 (PDE7) is a key enzyme involved in the degradation of intracellular levels of cyclic adenosine 3′, 5′-monophosphate in different cell types; however, little is known regarding its role in neurodegenerative diseases, and specifically in Parkinson’s disease. We have previously shown that chemical as well as genetic inhibition of this enzyme results in neuroprotection and anti-inflammatory activity in different models of neurodegenerative disorders, including Parkinson’s disease. Here, we have used in vitro and in vivo models of Parkinson’s disease to study the regulation of PDE7 protein levels. Our results show that PDE7 is upregulated after an injury both in the human dopaminergic cell line SH-SY5Y and in primary rat mesencephalic cultures and after lipopolysaccharide or 6-hidroxydopamine injection in the Substantia nigra pars compacta of adult mice. PDE7 increase takes place mainly in degenerating dopaminergic neurons and in microglia cells. This enhanced expression appears to be direct since 6-hydroxydopamine and lipopolysaccharide increase the expression of a 962-bp fragment of its promoter. Taking together, these results reveal an essential function for PDE7 in the pathways leading to neurodegeneration and inflammatory-mediated brain damage and suggest novel roles for PDE7 in neurodegenerative diseases, specifically in PD, opening the door for new therapeutic interventions.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Glial fibrillary acidic protein
Substantia nigra pars compacta
Michel PP, Hirsch EC, Hunot S (2016) Understanding dopaminergic cell death pathways in Parkinson disease. Neuron 90(4):675–691. https://doi.org/10.1016/j.neuron.2016.03.038
Kulkarni OP, Lichtnekert J, Anders HJ, Mulay SR (2016) The immune system in tissue environments regaining homeostasis after injury: is “inflammation” always inflammation? Mediat Inflamm 2016:2856213. https://doi.org/10.1155/2016/2856213
Shabab T, Khanabdali R, Moghadamtousi SZ, Kadir HA, Mohan G (2017) Neuroinflammation pathways: a general review. Int. J. Neurosci. 127(7):624–633. https://doi.org/10.1080/00207454.2016.1212854
Ransohoff RM (2016) How neuroinflammation contributes to neurodegeneration. Science 353(6301):777–783. https://doi.org/10.1126/science.aag2590
Russo MV, McGavern DB (2016) Inflammatory neuroprotection following traumatic brain injury. Science 353(6301):783–785. https://doi.org/10.1126/science.aaf6260
Colonna M, Butovsky O (2017) Microglia function in the central nervous system during health and neurodegeneration. Annu Rev Immunol 35:441–468. https://doi.org/10.1146/annurev-immunol-051116-052358
Perry VH, Nicoll JA, Holmes C (2010) Microglia in neurodegenerative disease. Nat Rev Neurol 6(4):193–201. https://doi.org/10.1038/nrneurol.2010.17
Hirsch EC, Vyas S, Hunot S (2012) Neuroinflammation in Parkinson’s disease. Parkinsonism Relat Disord 18(Suppl 1):S210–S212. https://doi.org/10.1016/S1353-8020(11)70065-7
Chen WW, Zhang X, Huang WJ (2016) Role of neuroinflammation in neurodegenerative diseases (review). Mol Med Rep 13(4):3391–3396. https://doi.org/10.3892/mmr.2016.4948
Heneka MT, Kummer MP, Latz E (2014) Innate immune activation in neurodegenerative disease. Nat Rev Immunol 14(7):463–477. https://doi.org/10.1038/nri3705
Pal R, Tiwari PC, Nath R, Pant KK (2016) Role of neuroinflammation and latent transcription factors in pathogenesis of Parkinson’s disease. Neurol Res 38(12):1111–1122. https://doi.org/10.1080/01616412.2016.1249997
Tansey MG, McCoy MK, Frank-Cannon TC (2007) Neuroinflammatory mechanisms in Parkinson’s disease: potential environmental triggers, pathways, and targets for early therapeutic intervention. Exp Neurol 208(1):1–25. https://doi.org/10.1016/j.expneurol.2007.07.004
Conti M, Beavo J (2007) Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu Rev Biochem 76:481–511. https://doi.org/10.1146/annurev.biochem.76.060305.150444
Bender AT, Beavo JA (2006) Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev 58(3):488–520. https://doi.org/10.1124/pr.58.3.5
Kelly MP (2018) Cyclic nucleotide signaling changes associated with normal aging and age-related diseases of the brain. Cell Signal 42:281–291. https://doi.org/10.1016/j.cellsig.2017.11.004
Ffytche DH, Creese B, Politis M, Chaudhuri KR, Weintraub D, Ballard C, Aarsland D (2017) The psychosis spectrum in Parkinson disease. Nat Rev Neurol 13(2):81–95. https://doi.org/10.1038/nrneurol.2016.200
Lugnier C (2006) Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol Ther 109(3):366–398. https://doi.org/10.1016/j.pharmthera.2005.07.003
Dyke HJ, Montana JG (2002) Update on the therapeutic potential of PDE4 inhibitors. Expert Opin Investig Drugs 11(1):1–13. https://doi.org/10.1517/135437188.8.131.52
Spina D (2003) Phosphodiesterase-4 inhibitors in the treatment of inflammatory lung disease. Drugs 63(23):2575–2594. https://doi.org/10.2165/00003495-200363230-00002
Bloom TJ, Beavo JA (1996) Identification and tissue-specific expression of PDE7 phosphodiesterase splice variants. Proc Natl Acad Sci U S A 93(24):14188–14192
Sasaki T, Kotera J, Omori K (2002) Novel alternative splice variants of rat phosphodiesterase 7B showing unique tissue-specific expression and phosphorylation. Biochem. J. 361 (Pt 2:211–220
Miro X, Perez-Torres S, Palacios JM, Puigdomenech P, Mengod G (2001) Differential distribution of cAMP-specific phosphodiesterase 7A mRNA in rat brain and peripheral organs. Synapse 40(3):201–214. https://doi.org/10.1002/syn.1043
Reyes-Irisarri E, Perez-Torres S, Mengod G (2005) Neuronal expression of cAMP-specific phosphodiesterase 7B mRNA in the rat brain. Neuroscience 132(4):1173–1185. https://doi.org/10.1016/j.neuroscience.2005.01.050
Morales-Garcia JA, Redondo M, Alonso-Gil S, Gil C, Perez C, Martinez A, Santos A, Perez-Castillo A (2011) Phosphodiesterase 7 inhibition preserves dopaminergic neurons in cellular and rodent models of Parkinson disease. PLoS One 6(2):e17240. https://doi.org/10.1371/journal.pone.0017240
Morales-Garcia JA, Alonso-Gil S, Gil C, Martinez A, Santos A, Perez-Castillo A (2015) Phosphodiesterase 7 inhibition induces dopaminergic neurogenesis in hemiparkinsonian rats. Stem Cells Transl Med 4(6):564–575. https://doi.org/10.5966/sctm.2014-0277
Morales-Garcia JA, Echeverry-Alzate V, Alonso-Gil S, Sanz-SanCristobal M, Lopez-Moreno JA, Gil C, Martinez A, Santos A et al (2017) Phosphodiesterase7 inhibition activates adult neurogenesis in hippocampus and subventricular zone in vitro and in vivo. Stem Cells 35(2):458–472. https://doi.org/10.1002/stem.2480
Bibb JA (2005) Decoding dopamine signaling. Cell 122(2):153–155. https://doi.org/10.1016/j.cell.2005.07.011
Sasaki T, Kotera J, Omori K (2004) Transcriptional activation of phosphodiesterase 7B1 by dopamine D1 receptor stimulation through the cyclic AMP/cyclic AMP-dependent protein kinase/cyclic AMP-response element binding protein pathway in primary striatal neurons. J Neurochem 89(2):474–483. https://doi.org/10.1111/j.1471-4159.2004.02354.x
Morales-Garcia JA, Palomo V, Redondo M, Alonso-Gil S, Gil C, Martinez A, Perez-Castillo A (2014) Crosstalk between phosphodiesterase 7 and glycogen synthase kinase-3: two relevant therapeutic targets for neurological disorders. ACS Chem Neurosci 5(3):194–204. https://doi.org/10.1021/cn400166d
Morales-Garcia JA, de la Fuente RM, Alonso-Gil S, Rodriguez-Franco MI, Feilding A, Perez-Castillo A, Riba J (2017) The alkaloids of Banisteriopsis caapi, the plant source of the Amazonian hallucinogen Ayahuasca, stimulate adult neurogenesis in vitro. Sci Rep 7(1):5309. https://doi.org/10.1038/s41598-017-05407-9
Morales-Garcia JA, Gine E, Hernandez-Encinas E, Aguilar-Morante D, Sierra-Magro A, Sanz-SanCristobal M, Alonso-Gil S, Sanchez-Lanzas R et al (2017) CCAAT/Enhancer binding protein beta silencing mitigates glial activation and neurodegeneration in a rat model of Parkinson’s disease. Sci Rep 7(1):13526. https://doi.org/10.1038/s41598-017-13269-4
Paxinos G, Watson C (2007) The rat brain in stereotaxic coordinates. 6th edn. Academic Press/Elsevier, Amsterdam
Barnes MJ, Cooper N, Davenport RJ, Dyke HJ, Galleway FP, Galvin FC, Gowers L, Haughan AF et al (2001) Synthesis and structure-activity relationships of guanine analogues as phosphodiesterase 7 (PDE7) inhibitors. Bioorg Med Chem Lett 11(8):1081–1083
Pitts WJ, Vaccaro W, Huynh T, Leftheris K, Roberge JY, Barbosa J, Guo J, Brown B et al (2004) Identification of purine inhibitors of phosphodiesterase 7 (PDE7). Bioorg Med Chem Lett 14(11):2955–2958. https://doi.org/10.1016/j.bmcl.2004.03.021
Vergne F, Bernardelli P, Lorthiois E, Pham N, Proust E, Oliveira C, Mafroud AK, Royer F et al (2004) Discovery of thiadiazoles as a novel structural class of potent and selective PDE7 inhibitors. Part 1: design, synthesis and structure-activity relationship studies. Bioorg Med Chem Lett 14(18):4607–4613. https://doi.org/10.1016/j.bmcl.2004.07.008
Persson M, Brantefjord M, Hansson E, Ronnback L (2005) Lipopolysaccharide increases microglial GLT-1 expression and glutamate uptake capacity in vitro by a mechanism dependent on TNF-alpha. Glia 51(2):111–120. https://doi.org/10.1002/glia.20191
Hersch SM, Yi H, Heilman CJ, Edwards RH, Levey AI (1997) Subcellular localization and molecular topology of the dopamine transporter in the striatum and substantia nigra. J Comp Neurol 388(2):211–227
Anderson KD, Reiner A (1991) Immunohistochemical localization of DARPP-32 in striatal projection neurons and striatal interneurons: implications for the localization of D1-like dopamine receptors on different types of striatal neurons. Brain Res 568(1–2):235–243. https://doi.org/10.1016/0006-8993(91)91403-n
Obeso JA, Rodriguez-Oroz MC, Goetz CG, Marin C, Kordower JH, Rodriguez M, Hirsch EC, Farrer M et al (2010) Missing pieces in the Parkinson’s disease puzzle. Nat Med 16(6):653–661. https://doi.org/10.1038/nm.2165
Maurice DH, Ke H, Ahmad F, Wang Y, Chung J, Manganiello VC (2014) Advances in targeting cyclic nucleotide phosphodiesterases. Nat Rev Drug Discov 13(4):290–314. https://doi.org/10.1038/nrd4228
Ribaudo G, Pagano MA, Bova S, Zagotto G (2016) New therapeutic applications of phosphodiesterase 5 inhibitors (PDE5-Is). Curr Med Chem 23(12):1239–1249
Li P, Zheng H, Zhao J, Zhang L, Yao W, Zhu H, Beard JD, Ida K et al (2016) Discovery of potent and selective inhibitors of phosphodiesterase 1 for the treatment of cognitive impairment associated with neurodegenerative and neuropsychiatric diseases. J Med Chem 59(3):1149–1164. https://doi.org/10.1021/acs.jmedchem.5b01751
Soares LM, Meyer E, Milani H, Steinbusch HW, Prickaerts J, de Oliveira RM (2017) The phosphodiesterase type 2 inhibitor BAY 60-7550 reverses functional impairments induced by brain ischemia by decreasing hippocampal neurodegeneration and enhancing hippocampal neuronal plasticity. Eur J Neurosci 45(4):510–520. https://doi.org/10.1111/ejn.13461
Nthenge-Ngumbau DN, Mohanakumar KP (2018) Can cyclic nucleotide phosphodiesterase inhibitors be drugs for Parkinson’s disease? Mol Neurobiol 55(1):822–834. https://doi.org/10.1007/s12035-016-0355-8
Perez-Gonzalez R, Pascual C, Antequera D, Bolos M, Redondo M, Perez DI, Perez-Grijalba V, Krzyzanowska A et al (2013) Phosphodiesterase 7 inhibitor reduced cognitive impairment and pathological hallmarks in a mouse model of Alzheimer’s disease. Neurobiol Aging 34(9):2133–2145. https://doi.org/10.1016/j.neurobiolaging.2013.03.011
Paterniti I, Mazzon E, Gil C, Impellizzeri D, Palomo V, Redondo M, Perez DI, Esposito E et al (2011) PDE 7 inhibitors: new potential drugs for the therapy of spinal cord injury. PLoS One 6(1):e15937. https://doi.org/10.1371/journal.pone.0015937
Redondo M, Zarruk JG, Ceballos P, Perez DI, Perez C, Perez-Castillo A, Moro MA, Brea J et al (2012) Neuroprotective efficacy of quinazoline type phosphodiesterase 7 inhibitors in cellular cultures and experimental stroke model. Eur J Med Chem 47(1):175–185. https://doi.org/10.1016/j.ejmech.2011.10.040
Martin-Alvarez R, Paul-Fernandez N, Palomo V, Gil C, Martinez A, Mengod G (2017) A preliminary investigation of phoshodiesterase 7 inhibitor VP3.15 as therapeutic agent for the treatment of experimental autoimmune encephalomyelitis mice. J Chem Neuroanat 80:27–36. https://doi.org/10.1016/j.jchemneu.2016.12.001
Mestre L, Redondo M, Carrillo-Salinas FJ, Morales-Garcia JA, Alonso-Gil S, Perez-Castillo A, Gil C, Martinez A et al (2015) PDE7 inhibitor TC3.6 ameliorates symptomatology in a model of primary progressive multiple sclerosis. Br J Pharmacol 172(17):4277–4290. https://doi.org/10.1111/bph.13192
Morales-Garcia JA, Aguilar-Morante D, Hernandez-Encinas E, Alonso-Gil S, Gil C, Martinez A, Santos A, Perez-Castillo A (2015) Silencing phosphodiesterase 7B gene by lentiviral-shRNA interference attenuates neurodegeneration and motor deficits in hemiparkinsonian mice. Neurobiol Aging 36(2):1160–1173. https://doi.org/10.1016/j.neurobiolaging.2014.10.008
Johansson EM, Reyes-Irisarri E, Mengod G (2012) Comparison of cAMP-specific phosphodiesterase mRNAs distribution in mouse and rat brain. Neurosci Lett 525(1):1–6. https://doi.org/10.1016/j.neulet.2012.07.050
Hoffmann R, Abdel’Al S, Engels P (1998) Differential distribution of rat PDE-7 mRNA in embryonic and adult rat brain. Cell Biochem Biophys 28(2–3):103–113. https://doi.org/10.1007/BF02737807
Giembycz MA, Smith SJ (2006) Phosphodiesterase 7A: a new therapeutic target for alleviating chronic inflammation? Curr Pharm Des 12(25):3207–3220
Nakata A, Ogawa K, Sasaki T, Koyama N, Wada K, Kotera J, Kikkawa H, Omori K et al (2002) Potential role of phosphodiesterase 7 in human T cell function: comparative effects of two phosphodiesterase inhibitors. Clin Exp Immunol 128(3):460–466
We thank Monica Belinchon, expert in confocal images, for her technical support with the confocal microscope and Victor Echeverry, Jose Antonio Lopez-Moreno and Manuel Guzman from the Complutense University for kindly providing us with DAT and DARPP32 antibodies.
This work was financially supported by the Spanish Ministry of Economy and Competitiveness (grants SAF2014-52940-R and SAF2017-85199-P to A.P-C) and partially financed with FEDER funds. The Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED) is funded by the Institute for Health “Carlos III.” J.A.M-G. is a post-doctoral fellow from CIBERNED.
All applicable international, national, and/or institutional guidelines for the care and use of animals were followed. All animal experiments were specifically approved by the “Ethics Committee for Animal Experimentation” of the Instituto de Investigaciones Biomedicas (CSIC-UAM) and carried out in accordance with the European Communities Council Directive (2010/63/EEC) and National regulations (normative 53/2013).
Conflict of Interest
The authors declare that they have no conflict of interest.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Morales-Garcia, J.A., Alonso-Gil, S., Santos, Á. et al. Phosphodiesterase 7 Regulation in Cellular and Rodent Models of Parkinson’s Disease. Mol Neurobiol 57, 806–822 (2020). https://doi.org/10.1007/s12035-019-01745-z
- Microglial cells